Is INFECTION a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed INFECTION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 22 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported INFECTION to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and INFECTION. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause INFECTION, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes INFECTION. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if INFECTION ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing INFECTION: 22
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where INFECTION is a reported side effect: 0.6609%

FDA reports of any drug causing INFECTION : 31556
Average percentage for all medicated patients where INFECTION is reported as a complication: 0.1978%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with INFECTION:

FOSAMAX (4122 patients)
ZOMETA (3751 patients)
ASPIRIN (2294 patients)
AREDIA (2250 patients)
PREDNISONE (2010 patients)
HUMIRA (1896 patients)
METHOTREXATE (1554 patients)
DEXAMETHASONE (1521 patients)
CYCLOPHOSPHAMIDE (1434 patients)
REMICADE (1375 patients)
ENBREL (1340 patients)
REVLIMID (1330 patients)
LASIX (1328 patients)
COUMADIN (1120 patients)
VIOXX (1105 patients)
PREDNISOLONE (1066 patients)
DIANEAL (1045 patients)
AVONEX (1006 patients)
LIPITOR (998 patients)
FOLIC ACID (996 patients)
HEPARIN SODIUM INJECTION (992 patients)
TYSABRI (983 patients)
OXYCONTIN (977 patients)
NEXIUM (945 patients)
OMEPRAZOLE (895 patients)
NEURONTIN (873 patients)
FUROSEMIDE (849 patients)
LISINOPRIL (848 patients)
PROTONIX (845 patients)
VINCRISTINE (827 patients)
DECADRON (814 patients)
FORTEO (789 patients)
SYNTHROID (770 patients)
PREDNISONE TAB (766 patients)
ACETAMINOPHEN (752 patients)
XANAX (714 patients)
PERCOCET (686 patients)
DOXORUBICIN HCL (686 patients)
CELEBREX (684 patients)
SIMVASTATIN (672 patients)
VELCADE (670 patients)
ATENOLOL (669 patients)
PRILOSEC (668 patients)
ALLOPURINOL (667 patients)
ATIVAN (662 patients)
EXJADE (658 patients)
LEVAQUIN (647 patients)
ZOLOFT (633 patients)
ZOFRAN (633 patients)
CLOZARIL (631 patients)
VICODIN (629 patients)
OXYCODONE HCL (629 patients)
AMBIEN (620 patients)
HYDROCHLOROTHIAZIDE (615 patients)
THALIDOMIDE (614 patients)
POTASSIUM CHLORIDE (612 patients)
NORVASC (590 patients)
RITUXIMAB (578 patients)
CYCLOSPORINE (571 patients)
ACYCLOVIR (567 patients)
CALCIUM (562 patients)
MORPHINE (558 patients)
CARBOPLATIN (554 patients)
ARANESP (552 patients)
VITAMIN D (549 patients)
NEUPOGEN (543 patients)
CHEMOTHERAPEUTICS NOS (543 patients)
AMOXICILLIN (541 patients)
PREVACID (526 patients)
LORAZEPAM (518 patients)
CYTARABINE (517 patients)
ALBUTEROL (516 patients)
GABAPENTIN (511 patients)
LYRICA (511 patients)
FLUOROURACIL (509 patients)
ZOCOR (508 patients)
IBUPROFEN (508 patients)
RADIATION THERAPY (505 patients)
TAXOTERE (496 patients)
PLAVIX (486 patients)
NEORAL (482 patients)
FLUCONAZOLE (471 patients)
WARFARIN SODIUM (466 patients)
LORTAB (464 patients)
XELODA (464 patients)
DURAGESIC-100 (462 patients)
SEROQUEL (460 patients)
LIORESAL (460 patients)
CYMBALTA (459 patients)
ETOPOSIDE (456 patients)
LEVOTHYROXINE SODIUM (453 patients)
LEXAPRO (444 patients)
CIPROFLOXACIN (438 patients)
CISPLATIN (433 patients)
VANCOMYCIN (420 patients)
MULTI-VITAMINS (420 patients)
DIGOXIN (417 patients)
PREMARIN (402 patients)
ZANTAC (397 patients)
HERCEPTIN (396 patients)
CLINDAMYCIN (392 patients)
PAXIL (391 patients)
DIOVAN (388 patients)
INSULIN (385 patients)
METOPROLOL TARTRATE (380 patients)
FEMARA (377 patients)
MYCOPHENOLATE MOFETIL (376 patients)
METHYLPREDNISOLONE (376 patients)
FENTANYL (375 patients)
DIFLUCAN (374 patients)
ADVAIR DISKUS 100/50 (374 patients)
FOSAMAX PLUS D (372 patients)
COMPAZINE (368 patients)
BACTRIM (366 patients)
METFORMIN HCL (365 patients)
CYTOXAN (365 patients)
LOVENOX (362 patients)
AVASTIN (361 patients)
COLACE (358 patients)
SANDOSTATIN LAR (358 patients)
LANTUS (358 patients)
DILAUDID (357 patients)
TAMOXIFEN CITRATE (355 patients)
GLEEVEC (354 patients)
CHLORHEXIDINE GLUCONATE (352 patients)
ZITHROMAX (350 patients)
ARIMIDEX (343 patients)
TAXOL (337 patients)
CEPHALEXIN (336 patients)
TOPROL-XL (332 patients)
CALCIUM CARBONATE (331 patients)
PACLITAXEL (330 patients)
TACROLIMUS (327 patients)
PROGRAF (323 patients)
CAPECITABINE (321 patients)
CELEXA (320 patients)
ZYPREXA (320 patients)
ALENDRONATE SODIUM (318 patients)
ADRIAMYCIN PFS (317 patients)
REGLAN (316 patients)
OXALIPLATIN (316 patients)
LANSOPRAZOLE (313 patients)
PROCRIT /00909301/ (313 patients)
PERIDEX (309 patients)
MS CONTIN (306 patients)
AMLODIPINE (305 patients)
FASLODEX (304 patients)
VITAMIN B-12 (304 patients)
REBIF (299 patients)
MORPHINE SULFATE (299 patients)
NEULASTA (297 patients)
ACTONEL (296 patients)
ASCORBIC ACID (294 patients)
EFFEXOR (293 patients)
LOPRESSOR (288 patients)
SOLIRIS (287 patients)
BEVACIZUMAB (287 patients)
THALOMID (286 patients)
SINGULAIR (282 patients)
VITAMIN E (282 patients)
AUGMENTIN '125' (281 patients)
HEPARIN (276 patients)
FAMOTIDINE (274 patients)
NYSTATIN (274 patients)
CRESTOR (274 patients)
DOXYCYCLINE (274 patients)
FLOMAX (272 patients)
DOCETAXEL (270 patients)
FLAGYL (269 patients)
EPOGEN (267 patients)
MELPHALAN (262 patients)
CIPRO (262 patients)
METRONIDAZOLE (262 patients)
ALPRAZOLAM (259 patients)
VIDAZA (259 patients)
TRAMADOL HCL (259 patients)
ACTOS (257 patients)
HUMALOG (255 patients)
FLONASE (254 patients)
WELLBUTRIN (254 patients)
TYLENOL (251 patients)
CLONAZEPAM (251 patients)
PROZAC (251 patients)
AVELOX (249 patients)
ANTIBIOTICS (249 patients)
ENALAPRIL MALEATE (249 patients)
COREG (248 patients)
BACLOFEN (248 patients)
TRACLEER (243 patients)
METOCLOPRAMIDE (243 patients)
FLUDARABINE PHOSPHATE (243 patients)
ROCEPHIN (241 patients)
ZYRTEC (239 patients)
BENADRYL (239 patients)
IRON (238 patients)
OXYCODONE (237 patients)
COZAAR (237 patients)
NITROGLYCERIN (237 patients)
PAMIDRONATE DISODIUM (235 patients)
PANTOPRAZOLE (235 patients)
SPIRIVA (234 patients)
TYLENOL (CAPLET) (233 patients)
MELPHALAN HYDROCHLORIDE (233 patients)
RAMIPRIL (232 patients)
SPIRONOLACTONE (232 patients)
MULTI-VITAMIN (232 patients)
METOPROLOL (232 patients)
NAVELBINE (228 patients)
FLEXERIL (228 patients)
PEPCID (227 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about INFECTION and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.